Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia

Expert Rev Proteomics. 2022 Feb;19(2):73-76. doi: 10.1080/14789450.2022.2067530. Epub 2022 Apr 22.

Authors

Håkon Reikvam^{1

2}, Anette Lodvir Hemsing^{1

2}, Maria Hernandez-Valladares^{1

3

4}, Even Birkeland³

Affiliations

¹ Department of Clinical Science, University of Bergen, Bergen, Norway.
² Department of Medicine, Haukeland University Hospital, Bergen, Norway.
³ Department of Biomedicine, University of Bergen, Bergen, Norway.
⁴ Department of Physical Chemistry, University of Granada, Granada, Spain.

PMID: 35436165
DOI: 10.1080/14789450.2022.2067530

No abstract available

Keywords: Acute myelogenous leukemia; mass spectrometry; proteomic profiling; reverse phase protein arrays; targeted therapy.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Protein Array Analysis
Proteomics*